Also, inhibition of off-target tyrosine kinases that circumvent FLT3 inhibitors should be detected, such as FLT1, FLT4, PDGFRα, and PDGFRβ (like compound 27), to elucidate the efficacy of these novel FLT3 inhibitors versus resistant AML cells. The gene discussed is PDGFRB; the disease is acute myeloid leukemia.